Skip to main content

Advertisement

Table 3 IRS2 SNP and haplotype associations with breast cancer

From: Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II

     Matching adjusteda Multivariate adjustedb
SNP Alleles Cases Controls OR (95% CI) P valuec OR (95% CI) P valuec
IRS2 rs9515118         
  G/G 386 404 1.00 (-)   1.00 (-)  
  G/C 201 201 1.06 (0.83–1.34)   1.07 (0.83–1.37)  
  C/C 28 23 1.28 (0.72–2.29) 0.43 1.28 (0.70–2.31) 0.40
  G/C or C/C 229 224 1.08 (0.85–1.36) 0.54 1.09 (0.86–1.38) 0.49
  rs4773082         
  T/T 157 205 1.00 (-)   1.00 (-)  
  T/C 327 299 1.43 (1.10–1.86)   1.46 (1.12–1.91)  
  C/C 156 146 1.40 (1.03–1.91) 0.024 1.31 (0.96–1.80) 0.07
  T/C or C/C 483 445 1.42 (1.11–1.82) 0.005 1.41 (1.10–1.81) 0.007
  rs2289046         
  A/A 275 248 1.00 (-)   1.00 (-)  
  A/G 245 284 0.78 (0.61–0.99)   0.79 (0.61–1.01)  
  G/G 32 57 0.51 (0.32–0.81) 0.0018 0.52 (0.32–0.84) 0.004
  A/G or G/G 277 341 0.73 (0.58–0.92) 0.009 0.74 (0.58–0.94) 0.016
  rs754204         
  C/C 155 198 1.00 (-)   1.00 (-)  
  C/T 328 315 1.33 (1.02–1.73)   1.32 (1.01–1.73)  
  T/T 159 142 1.43 (1.05–1.94) 0.022 1.32 (0.96–1.82) 0.07
  C/T or T/T 487 457 1.36 (1.06–1.74) 0.015 1.32 (1.03–1.70) 0.03
  rs7987237         
  C/C 470 491 1.00 (-)   1.00 (-)  
  C/T 156 149 1.10 (0.85–1.43)   1.17 (0.90–1.53)  
  T/T 15 11 1.50 (0.68–3.31) 0.27 1.56 (0.70–3.50) 0.13
  C/T or T/T 171 160 1.13 (0.88–1.45) 0.35 1.20 (0.93–1.55) 0.17
  rs12584136         
  C/C 579 588 1.00 (-)   1.00 (-)  
  C/A 54 56 0.98 (0.66–1.44)   0.96 (0.64–1.43)  
  A/A 4 3 1.31 (0.29–5.88) 0.96 1.44 (0.31–6.71) 0.98
  C/A or A/A 58 59 0.99 (0.68–1.45) 0.97 0.98 (0.67–1.45) 0.93
  rs9559648         
  C/C 269 306 1.00 (-)   1.00 (-)  
  C/T 304 268 1.29 (1.02–1.62)   1.30 (1.03–1.65)  
  T/T 66 73 1.02 (0.71–1.49) 0.27 0.97 (0.66–1.42) 0.34
  C/T or T/T 370 341 1.23 (0.99–1.53) 0.07 1.23 (0.98–1.54) 0.07
  rs9559654         
  G/G 301 317 1.00 (-)   1.00 (-)  
  G/A 248 250 1.05 (0.83–1.33)   1.05 (0.82–1.34)  
  A/A 67 59 1.19 (0.81–1.75) 0.39 1.19 (0.80–1.76) 0.40
  G/A or A/A 315 309 1.07 (0.86–1.34) 0.52 1.08 (0.86–1.35) 0.52
  rs7997595         
  C/C 434 453 1.00 (-)   1.00 (-)  
  C/G 161 170 0.99 (0.77–1.28)   1.02 (0.79–1.32)  
  G/G 19 9 2.24 (1.00–5.01) 0.34 2.31 (1.02–5.24) 0.23
  C/G or G/G 180 179 1.05 (0.82–1.35) 0.68 1.09 (0.84–1.40) 0.50
  rs7981705         
  C/C 435 470 1.00 (-)   1.00 (-)  
  C/T 190 164 1.25 (0.98–1.60)   1.17 (0.91–1.51)  
  T/T 17 19 0.99 (0.50–1.93) 0.16 0.90 (0.45–1.79) 0.43
  C/T or T/T 207 183 1.23 (0.97–1.56) 0.09 1.14 (0.89–1.46) 0.29
  rs4773092         
  G/G 152 170 1.00 (-)   1.00 (-)  
  G/A 333 303 1.24 (0.95–1.62)   1.21 (0.92–1.60)  
  A/A 132 118 1.28 (0.92–1.78) 0.12 1.30 (0.93–1.82) 0.11
  G/A or A/A 465 421 1.25 (0.97–1.62) 0.08 1.24 (0.95–1.61) 0.11
Haplotypes of rs4773082, rs2289046, and rs754204 CAT 296.8 273.2 1.00 -   1.00 -  
  TGC 188.8 227.4 0.74 (0.62–0.90) 0.0018 0.76 (0.63–0.92) 0.0050
  TAC 107.3 104.6 0.99 (0.78–1.24) 0.89 1.04 (0.82–1.32) 0.75
  Other groups 52.2 49.9 0.98 (0.72–1.33) 0.88 0.96 (0.70–1.32) 0.80
     Global P value = 0.015 Global P value = 0.030
  1. aAdjusted for race, birth date, and blood draw date. bAdjusted for race, birth date, blood draw date, adult weight change, breast cysts, family history of breast cancer, and hormone replacement therapy use. cFor IRS2 P values are provided for the log-additive model, and the dominant model; for Haplotypes of rs4773082, rs2289046, and rs754204, haplotype P values are compared with the most common haplotype. CI, confidence interval; IRS2, insulin receptor substrate 2 gene; OR, odds ratio.